Diehl V - Search Results

1

Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.

Engert A, Gottstein C, Winkler U, Amlot P, Pileri S, Diehl V, Thorpe P. Engert A, et al. Among authors: diehl v. Leuk Lymphoma. 1994 May;13(5-6):441-8. doi: 10.3109/10428199409049633. Leuk Lymphoma. 1994. PMID: 8069189 Review.

2

[New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].

Engert A, Gottstein C, Winkler U, Schön G, Amlot P, Thorpe P, Diehl V. Engert A, et al. Among authors: diehl v. Med Klin (Munich). 1992 Oct 15;87(10):503-9. Med Klin (Munich). 1992. PMID: 1461215 Review. German.

3

Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.

Engert A, Gottstein C, Bohlen H, Winkler U, Schön G, Manske O, Schnell R, Diehl V, Thorpe P. Engert A, et al. Among authors: diehl v. Int J Cancer. 1995 Oct 9;63(2):304-9. doi: 10.1002/ijc.2910630226. Int J Cancer. 1995. PMID: 7591221

4

Immunotoxins: is there a clinical value?

Gottstein C, Winkler U, Bohlen H, Diehl V, Engert A. Gottstein C, et al. Among authors: diehl v. Ann Oncol. 1994;5 Suppl 1:97-103. doi: 10.1093/annonc/5.suppl_1.s97. Ann Oncol. 1994. PMID: 7826425 Review.

5

Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.

Gottstein C, Schön G, Tawadros S, Kube D, Wargalla-Plate UC, Hansmann ML, Wacker HH, Berthold F, Diehl V, Engert A. Gottstein C, et al. Among authors: diehl v. Cancer Res. 1994 Dec 1;54(23):6186-93. Cancer Res. 1994. PMID: 7954465

6

Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.

Winkler U, Gottstein C, Schön G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A. Winkler U, et al. Among authors: diehl v. Blood. 1994 Jan 15;83(2):466-75. Blood. 1994. PMID: 8286745 Free article.

7

Development of immunotoxins for potential clinical use in Hodgkin's disease.

Barth S, Schnell R, Diehl V, Engert A. Barth S, et al. Among authors: diehl v. Ann Oncol. 1996;7 Suppl 4:135-41. doi: 10.1093/annonc/7.suppl_4.s135. Ann Oncol. 1996. PMID: 8836425 Review.

8

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.

Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A. Schnell R, et al. Among authors: diehl v. Leuk Lymphoma. 1998 Aug;30(5-6):525-37. doi: 10.3109/10428199809057565. Leuk Lymphoma. 1998. PMID: 9711915 Clinical Trial.

9

Issues in the treatment of Hodgkin's disease.

Wolf J, Engert A, Diehl V. Wolf J, et al. Among authors: diehl v. Curr Opin Oncol. 1998 Sep;10(5):396-402. doi: 10.1097/00001622-199809000-00005. Curr Opin Oncol. 1998. PMID: 9800108 Review.

10

Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches.

Engert A, Wolf J, Diehl V. Engert A, et al. Among authors: diehl v. Semin Hematol. 1999 Jul;36(3):282-9. Semin Hematol. 1999. PMID: 10462328 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

839 results

Search Page